# Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer

> **NCT00923273** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** FDG-PET
- **DRUG:** Pemetrexed
- **DRUG:** Sirolimus
- **DIETARY_SUPPLEMENT:** Vitamin B12
- **DIETARY_SUPPLEMENT:** Folic acid tablets
- **DRUG:** Dexamethasone tablets

## Key facts

- **NCT ID:** NCT00923273
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02-29
- **Primary completion:** 2013-03-10
- **Final completion:** 2013-03-10
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Premature closure - investigator left the National Institutes of Health.
- **Last updated:** 2019-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923273, "Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00923273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*